CYCN
Cyclerion Therapeutics, Inc.NASDAQHealthcare$6.15-32.52%ClosedMarket Cap: $23.4M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.47
P/S
7.62
EV/EBITDA
-2.52
DCF Value
$0.93
FCF Yield
-21.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-239.8%
Net Margin
-170.1%
ROE
-39.2%
ROA
-35.3%
ROIC
-54.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2025 | $875.0K | 100.0% | $-1.0M | $-976.0K | $-0.30 | — |
| Q2 2025 | $93.0K | 100.0% | $-1.7M | $-324.0K | $-0.11 | — |
| Q1 2025 | $81.0K | 100.0% | $-1.5M | $-1.4M | $-0.56 | — |
| Q4 2024 | $1.8M | 100.0% | $502.0K | $530.0K | $0.21 | — |
| FY 2024 | $2.0M | 100.0% | $-3.6M | $-3.1M | $-1.21 | — |
| Q3 2024 | $194.0K | 100.0% | $-1.1M | $-723.0K | $-0.29 | — |
| Q2 2024 | $0.00 | NaN% | $-1.4M | $-1.3M | $-0.53 | — |
| Q1 2024 | $0.00 | NaN% | $-1.6M | $-1.5M | $-0.62 | — |
| Q4 2023 | $0.00 | NaN% | $-1.8M | $-1.7M | $-0.68 | — |
| FY 2023 | $0.00 | NaN% | $-13.0M | $-5.3M | $-8.99 | — |
| Q3 2023 | $0.00 | NaN% | $-6.0M | $7.6M | $-3.36 | — |
| Q2 2023 | $0.00 | -Infinity% | $-1.9M | $-4.2M | $-1.83 | — |